Stryker Corp. (SYK) filed a Form 8-K dated June 26, 2026, to report changes in how it presents its business segments following an organizational restructuring announced in the first quarter of 2026. The filing was made under Item 8.01, “Other Events,” and does not report a financing, acquisition, insider stock transaction, dividend, or change in control. Instead, it updates prior financial presentation to align with the company’s revised internal business structure. The key corporate action is the creation of a new “Ortho Tech” business within Stryker’s organization. The new unit combines the orthopaedic instruments portfolio from Stryker’s Instruments business with the Mako robotic and enabling technologies portfolio from its Other Orthopaedics business. Stryker said the purpose of the move is to bring together Mako, power tools, cutting accessories, enabling technologies and related teams under one business, simplifying the customer experience and improving speed to market through more focused innovation. Despite the internal reorganization, Stryker said it will continue to report two business segments: MedSurg and Neurotechnology, and Orthopaedics. Each of these continues to constitute a reportable segment. The change affects how certain historical results are presented across the company’s segment reporting, but it does not change Stryker’s previously reported consolidated financial results. To comply with SEC rules, Stryker is recasting its consolidated financial statements for each of the three years in the period ended December 31, 2025, so that historical information reflects the updated segment reporting structure. The company emphasized that the updates are not a restatement of previously issued financial statements. Rather, they are intended to make prior-period segment data comparable with Stryker’s current business organization. The recast information appears in Exhibit 99.1 to the Form 8-K, described as a recast of certain items from Stryker’s Annual Report on Form 10-K for the year ended December 31, 2025. The filing also includes Exhibit 23.1, the consent of the independent registered public accounting firm, along with inline XBRL-related exhibits. Stryker cautioned that the filing is presented for informational purposes only in connection with the segment reporting changes. It does not amend or restate the company’s audited consolidated financial statements included in the 2025 Annual Report, and it does not update management’s discussion and analysis for later developments, uncertainties, transactions, risks, events or trends. The company directed investors to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and other subsequent filings for more current information. The report was signed on June 26, 2026, by Preston W. Wells, Stryker’s Vice President and Chief Financial Officer.